Fundraising Fox
Urogen
Princeton, US · 4 known investors
Find your way into Urogen
Sign up to see every warm intro you have to Urogen
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Urogen team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
UroGen is a biotech company developing treatments for urothelial and specialty cancers using a proprietary sustained-release hydrogel platform technology. The company commercializes approved therapies for bladder and upper tract cancers, with additional candidates in development.
Founders & leadership
Board
Investors · 4
How we know: Aisling Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Monograph Capital Partners's portfolio page · Not right? Tell us
How we know: Pontifax Venture Capital's portfolio page · board seat on SEC Form D · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$120M disclosed across 1 round · 2023
▶$120MraisedAug 2023 · 8 investors · PharmaceuticalsRule 506(b)
- Stuart Holden, M.D.Director
- Jason SmithExecutive Officer
- Arie Belldegrun, M.D.Director
- Dan WildmanDirector
- Fred Cohen, M.D.Director
- Don KimExecutive Officer
- James A. Robinson, Jr.Director
- Cynthia ButittaDirector
- Ran NussbaumDirector
- Elizabeth BarrettExecutive Officer, Director
- Leana Wen, M.D., MScDirector
- Mark Schoenberg, M.D.Executive Officer
- Offering amount
- $120M
- Amount sold
- $120M
- Sales commissions
- $3.2M
- Placement agents
- H.C. Wainwright & Co., LLC, BofA Securities, Inc.
- First sale
- Jul 2023
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Urogen went on to found or lead other companies.
Frequently asked questions
- What does Urogen do?
- UroGen is a biotech company developing treatments for urothelial and specialty cancers using a proprietary sustained-release hydrogel platform technology. The company commercializes approved therapies for bladder and upper tract cancers, with additional candidates in development.
- Who are Urogen's investors?
- Urogen's investors include Aisling Capital, Monograph Capital Partners, Pontifax Venture Capital, Aravis Ventures.
- How much funding has Urogen raised?
- Urogen has disclosed $120M raised across 1 round.
- Where is Urogen headquartered?
- Urogen is headquartered in Princeton, US.